KIYATEC offers predictive, in-vitro, 3D primary tumor screens
March 2015
by  |  Email the author

SHARING OPTIONS:

KIYATEC Inc.
 
KIYATEC prioritizes accurate ex-vivo prediction of patients’ drug response, focused primarily on data correlation to human clinical outcomes. Our drug response profiling services utilize phenotypic 3D cell-based models and primary patient tumors for predicting both chemotherapeutic and targeted agent drug response. KIYATEC’s 3D perfusion tissue microenvironments are particularly useful for investigating drug efficacy and modeling resistance of cancer therapeutics.
 
SEE US AT AACR BOOTH 2365
 
KIYATEC Inc.
Code:

Back
 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.